Literature DB >> 5281051

L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.

R L Capizzi, J R Bertino, R T Skeel, W A Creasey, R Zanes, C Olayon, R G Peterson, R E Handschumacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5281051     DOI： 10.7326/0003-4819-74-6-893

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  32 in total

1.  Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro.

Authors:  L Bartalena; E Martino; A Pacchiarotti; S Balzano; M Falcone; V Sica; P Biddau; A Pinchera
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

Review 2.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

3.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

4.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Authors:  C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

5.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.

Authors:  Jason R Cantor; Tae Hyeon Yoo; Aakanksha Dixit; Brent L Iverson; Thomas G Forsthuber; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-05       Impact factor: 11.205

Review 6.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

7.  A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.

Authors:  S-H Chen; W Yang; Y Fan; G Stocco; K R Crews; J J Yang; S W Paugh; C-H Pui; W E Evans; M V Relling
Journal:  Leukemia       Date:  2010-11-12       Impact factor: 11.528

Review 8.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

9.  Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.

Authors:  S L Berg; F M Balis; C L McCully; K S Godwin; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.

Authors:  H B Muss; N Spell; D Scudiery; R L Capizzi; M R Cooper; J Cruz; D V Jackson; F Richards; C L Spurr; D R White
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.